1-2 of 2
Satoshi Hara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

Akira Sugimoto, Shingo Matsumoto, Hibiki Udagawa, Ryo Itotani, Yuko Usui, Shigeki Umemura, Kazumi Nishino, Ichiro Nakachi, Shoichi Kuyama, Haruko Daga, Satoshi Hara, Shingo Miyamoto, Terufumi Kato, Jun Sakakibara-Konishi, Eriko Tabata, Taku Nakagawa, Tomoya Kawaguchi, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Koichi Goto
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1506–1514.
https://doi.org/10.1158/1078-0432.CCR-22-1749
Published: 14 April 2023
View article titled, A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Open the PDF for A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 893–902.
https://doi.org/10.1158/1078-0432.CCR-21-3194
Published: 01 March 2022
View article titled, A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Open the PDF for A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) in another window
Includes: Supplementary data